These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 17153752

  • 1. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
    Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752
    [No Abstract] [Full Text] [Related]

  • 2. COX-2 inhibitors--a lesson in unexpected problems.
    Drazen JM.
    N Engl J Med; 2005 Mar 17; 352(11):1131-2. PubMed ID: 15713947
    [No Abstract] [Full Text] [Related]

  • 3. Coxibs and cardiovascular disease.
    Fitzgerald GA.
    N Engl J Med; 2004 Oct 21; 351(17):1709-11. PubMed ID: 15470192
    [No Abstract] [Full Text] [Related]

  • 4. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Smith ER.
    Can J Cardiol; 2005 Mar 21; 21(3):307-8. PubMed ID: 15776124
    [No Abstract] [Full Text] [Related]

  • 5. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S, Spigset O, Slørdal L.
    Tidsskr Nor Laegeforen; 2005 Apr 07; 125(7):875-8. PubMed ID: 15815733
    [Abstract] [Full Text] [Related]

  • 6. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
    Meyer CH.
    Klin Monbl Augenheilkd; 2005 Jan 07; 222(1):62-3. PubMed ID: 15678404
    [No Abstract] [Full Text] [Related]

  • 7. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
    Messerli FH, Sichrovsky T.
    Am J Cardiol; 2005 Sep 15; 96(6):872-3. PubMed ID: 16169380
    [No Abstract] [Full Text] [Related]

  • 8. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J.
    Science; 2005 Feb 25; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract] [Full Text] [Related]

  • 9. The lessons of Vioxx.
    Frazier KC.
    N Engl J Med; 2005 Sep 29; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Life after Vioxx: the clinical implications.
    Fortun PJ, Hawkey CJ.
    Hosp Med; 2005 May 29; 66(5):264-7. PubMed ID: 15920854
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. COX-2 inhibitors and the heart: putting risk in perspective.
    Bobadilla RV, Barnett EM, Randels CL.
    Adv Nurse Pract; 2005 Nov 29; 13(11):48-50. PubMed ID: 16295003
    [No Abstract] [Full Text] [Related]

  • 18. The COX-2 inhibitors--an update.
    Furberg CD.
    Am Heart J; 2006 Aug 29; 152(2):197-9. PubMed ID: 16875896
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Rofecoxib, Merck, and the FDA.
    Wolfe MM.
    N Engl J Med; 2004 Dec 30; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.